161 related articles for article (PubMed ID: 8360181)
1. The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator.
Moser TL; Enghild JJ; Pizzo SV; Stack MS
J Biol Chem; 1993 Sep; 268(25):18917-23. PubMed ID: 8360181
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen and tissue-type plasminogen activator bind to immobilized fibronectin.
Salonen EM; Saksela O; Vartio T; Vaheri A; Nielsen LS; Zeuthen J
J Biol Chem; 1985 Oct; 260(22):12302-7. PubMed ID: 2413022
[TBL] [Abstract][Full Text] [Related]
3. Assignment of the binding site for tissue plasminogen activator on human fibronectin.
Wang L; Lin XH; Cui DF; Wang ZY; Chi CW
J Biol Chem; 1994 Feb; 269(6):4332-6. PubMed ID: 8308001
[TBL] [Abstract][Full Text] [Related]
4. Modulation of tissue plasminogen activator-catalyzed plasminogen activation by synthetic peptides derived from the amino-terminal heparin binding domain of fibronectin.
Stack MS; Pizzo SV
J Biol Chem; 1993 Sep; 268(25):18924-8. PubMed ID: 8360182
[TBL] [Abstract][Full Text] [Related]
5. Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells.
Moser TL; Enghild JJ; Pizzo SV; Stack MS
Biochem J; 1995 May; 307 ( Pt 3)(Pt 3):867-73. PubMed ID: 7537960
[TBL] [Abstract][Full Text] [Related]
6. Degradation of human plasma and extracellular matrix fibronectin by tissue type plasminogen activator and urokinase.
Marchina E; Barlati S
Int J Biochem Cell Biol; 1996 Oct; 28(10):1141-50. PubMed ID: 8930138
[TBL] [Abstract][Full Text] [Related]
7. Identification of fibronectin type I domains as amyloid-binding modules on tissue-type plasminogen activator and three homologs.
Maas C; Schiks B; Strangi RD; Hackeng TM; Bouma BN; Gebbink MF; Bouma B
Amyloid; 2008 Sep; 15(3):166-80. PubMed ID: 18925455
[TBL] [Abstract][Full Text] [Related]
8. Limited plasmin proteolysis of vitronectin. Characterization of the adhesion protein as morpho-regulatory and angiostatin-binding factor.
Kost C; Benner K; Stockmann A; Linder D; Preissner KT
Eur J Biochem; 1996 Mar; 236(2):682-8. PubMed ID: 8612645
[TBL] [Abstract][Full Text] [Related]
9. Fibronectin's III-1 module contains a conformation-dependent binding site for the amino-terminal region of fibronectin.
Hocking DC; Sottile J; McKeown-Longo PJ
J Biol Chem; 1994 Jul; 269(29):19183-7. PubMed ID: 8034677
[TBL] [Abstract][Full Text] [Related]
10. Domain-domain interactions in hybrids of tissue-type plasminogen activator and urokinase-type plasminogen activator.
Bakker AH; Nieuwenbroek NM; Verheijen JH
Protein Eng; 1995 Dec; 8(12):1295-1302. PubMed ID: 8869642
[TBL] [Abstract][Full Text] [Related]
11. The effect of substituted laminin A chain-derived peptides on the conformation and activation kinetics of plasminogen.
Stack MS; Pizzo SV
Arch Biochem Biophys; 1994 Feb; 309(1):117-22. PubMed ID: 8117101
[TBL] [Abstract][Full Text] [Related]
12. Modulation of murine B16F10 melanoma plasminogen activator production by a synthetic peptide derived from the laminin A chain.
Stack MS; Gray RD; Pizzo SV
Cancer Res; 1993 May; 53(9):1998-2004. PubMed ID: 8481902
[TBL] [Abstract][Full Text] [Related]
13. Binding of recombinant apolipoprotein(a) to extracellular matrix proteins.
van der Hoek YY; Sangrar W; Côté GP; Kastelein JJ; Koschinsky ML
Arterioscler Thromb; 1994 Nov; 14(11):1792-8. PubMed ID: 7947605
[TBL] [Abstract][Full Text] [Related]
14. Localization of two binding domains for thrombospondin within fibronectin.
Zafar RS; Zeng Z; Walz DA
Arch Biochem Biophys; 1992 Sep; 297(2):271-6. PubMed ID: 1497347
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic kringles derived from human plasminogen and apolipoprotein(a) inhibit fibrinolysis through a mechanism that requires a functional lysine-binding site.
Ahn JH; Lee HJ; Lee EK; Yu HK; Lee TH; Yoon Y; Kim SJ; Kim JS
Biol Chem; 2011 Apr; 392(4):347-56. PubMed ID: 21194375
[TBL] [Abstract][Full Text] [Related]
16. Fibronectin decreases the stimulatory effect of fibrin and fibrinogen fragment FCB-2 on plasmin formation by tissue plasminogen activator.
Beckmann R; Geiger M; de Vries C; Pannekoek H; Binder BR
J Biol Chem; 1991 Feb; 266(4):2227-32. PubMed ID: 1824940
[TBL] [Abstract][Full Text] [Related]
17. Extracellular matrix binding properties of recombinant fibronectin type II-like modules of human 72-kDa gelatinase/type IV collagenase. High affinity binding to native type I collagen but not native type IV collagen.
Steffensen B; Wallon UM; Overall CM
J Biol Chem; 1995 May; 270(19):11555-66. PubMed ID: 7744795
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibrinogen, fibrin, and the complex of D-dimer noncovalently linked to fragment E.
Stewart RJ; Fredenburgh JC; Weitz JI
J Biol Chem; 1998 Jul; 273(29):18292-9. PubMed ID: 9660794
[TBL] [Abstract][Full Text] [Related]
19. Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator.
Anglés-Cano E; Hervio L; Rouy D; Fournier C; Chapman JM; Laplaud M; Koschinsky ML
Chem Phys Lipids; 1994 Jan; 67-68():369-80. PubMed ID: 8187237
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of novel lysine-independent apolipoprotein(a)-binding sites in fibrin(ogen) alphaC-domains.
Tsurupa G; Ho-Tin-Noé B; Anglés-Cano E; Medved L
J Biol Chem; 2003 Sep; 278(39):37154-9. PubMed ID: 12853452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
